搜索筛选:
搜索耗时4.6229秒,为你在为你在102,285,761篇论文里面共找到 5 篇相符的论文内容
发布年度:
Lenalidomide(LEN)maintenance(MNTC)after high-dose melphalan and autologous stem cell transplant(ASCT
[会议论文] 作者:Michel Attal,Antonio Palumbo,Sarah A.Holstein,Valerie Lauwers-Cances,Maria Teresa Petrucci,Paul G.Richardson,
来源:2016年临床肿瘤学新进展学术研讨会 年份:2016
...
Upfront autologous stem cell transplantation(ASCT)versus novel agent-based therapy for multiple myel
[会议论文] 作者:Michele Cavo,Antonio Palumbo,Sonja Zweegman,Meletios A.Dimopoulos,Roman Hajek,Lucia Pantani,Meral Beksac,
来源:2016年临床肿瘤学新进展学术研讨会 年份:2016
...
ELOQUENT-2: A phase Ⅲ, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/w
[会议论文] 作者:Dimopoulos,Antonio Palumbo,Darrell White,Sebastian Grosicki,Ivan Spicka,Adam Walter-Croneck,Philippe,
来源:2015年临床肿瘤学新进展学术研讨会 年份:2015
...
Phase Ⅲ randomized controlled study of daratumumab,bortezomib,and dexamethasone(DVd)versus bortezomi
[会议论文] 作者:Antonio Palumbo,Asher Alban Akmal Chanan-Khan,Katja Weisel,Ajay K.Nooka,Tamas Masszi,Meral Beksac,Ivan,
来源:2016年临床肿瘤学新进展学术研讨会 年份:2016
...
Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients with relapsed mu
[会议论文] 作者:Meletios Dimopoulos,Philippe Moreau,Antonio Palumbo,Douglas Joshua,Ludek Pour,Roman Hájek,Thierry Facon,
来源:第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份:2015
Objective: ENDEAVOR (NCT01568866) is comparing Kd with Vd in patients with RMM.The primary endpoint is PFS.Secondary endpoints include OS, ORR, peripheral neuropathy (PN) rate, and safety....
相关搜索: